The 5-year survival probability was 57% in patients with FIB4>5.88, but 96% in those with FIB4<1.21. Of 5,569 patients (mean age 54 yrs, treatment naïve 83%) with baseline FIB4<1.21, none had liver transplantation or HCC/ascites within 5 years. Compared to those with FIB4<1.21, FIB4>5.88 was associated with higher risk of death (adjusted hazard ratio (aHR) 3.1), liver transplantation, HCC and ascites (all aHR >8.2). Conclusions: Fibrosis stage based on either biopsy or FIB4 was strongly associated with probabilities of survival and liver-related complications. Fibrosis stage F4 and FIB4>5.88 Akt inhibitor were associated with higher morbidity and mortality, whereas

those Neratinib nmr with FIB4<1.21 appear to have excellent 5-year prognoses. Table. 5-year probabilities (95% CI) of clinical endpoints by fibrosis stage. Endpoints Biopsy stage FIB4 group F4 F3 F0-2 >5.88 1.21 to 5.88 <1.21 (n=457) (n=299) (n=1628) (n=1907) (n=8324) (n=5569) Survival 0.81(.77-.85) 0.90(.86-.94)

0.97(.96-.98) 0.57(.57-.60) 0.90(.89-.90) 0.96(.96-.97) Liver transplant 0.23(.19-.27) 0.02(0-.04) 0.01(0-.01) 0.12(.ll-.14) 0.02(.01-.02) 0 HCC 0.17(.13-.21) 0.03(.01-.05) 0.0K.01-.02 0.06(.05-.07) 0.01(.01-.01) 0 Ascites 0.18(.l3-.22) 0.06(.03-.09) 0.02(.01-.02) 0.17(.15-.19) 0.02(.02-.02) 0 Disclosures: Stuart C. Gordon – Advisory Committees or Review Panels: Tibotec; Consulting: Merck, CVS Caremark, Gilead Sciences, BMS; Grant/Research Support: Roche/Genentech, Merck, Vertex Pharmaceuticals, Gilead Sciences, BMS, Abbott, Intercept Pharmaceuticals, Exalenz Sciences, Inc. The following people have nothing to disclose: Fu ie Xu, Jia Li, Talan Zhang, Loralee B. Rupp, Mei Lu, Anne C. Moorman, Phi ip R. Spradling, Eyasu H. Teshale, Joseph A. Boscarino, Vinutha Vijayadeva, Mark A. Schmidt, Scott D. Holmberg Background

and aim 5-year performances Niclosamide of FT and TE have been validated in CHC in 2 prospective cohorts, (Ngo 2006 and Vergniol 201 1) for survival [overall survival (OS), and survival without liver related complications (S-LRC)]. The long-term prognostic values on each LRC are unknown due to the limited sample size and follow-up. Patients and methods To increase the power, we pooled the updated individual data of these cohorts at 10 years. Patients (pts) with CHC were included if at least 1 FT and 1 TE were performed, and excluded if they had other cause of liver disease. The main endpoints (estimated using Kaplan-Meier and Cox) were survivals (S) without transplantation (LT), without liver related death (LRD), LRC, primary liver cancer (HCC), ascites (A), jaundice (J), encephalopathy (E), and variceal bleeding (VB). Pts with non-reliable FT (1.8%) and non-reliable TE (18%; P=0<0.001 vs FT) were excluded.